stockrowAbivax SA Sponsored ADR
ABVX Healthcare Biotechnology
- EPS
- −98.8%
- Free cash flow
- −48.3%
- Total debt
- −98.5%
Quarter to June 2026, against a year earlier
Follow ABVX
Alert me
Abivax SA Sponsored ADR (ABVX) Return on invested capital
Abivax SA Sponsored ADR's return on invested capital over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −208.9% (fiscal 2022) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 208.88 |
| FY2022 | −208.9% | (208.88) |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| CORT Corcept Therapeutics Incorporated compare | 15.0% |
| RYTM Rhythm Pharmaceuticals, Inc. compare | 0.00% |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 0.00% |
| AXSM Axsome Therapeutics, Inc. compare | 0.00% |
| CYTK Cytokinetics, Incorporated compare | 0.00% |
| ABVX Abivax SA Sponsored ADR | 0.00% |
| SYRE Spyre Therapeutics, Inc. compare | 0.00% |
| ORKA Oruka Therapeutics, Inc. compare | −40.2% |
| PRAX Praxis Precision Medicines, Inc. compare | −40.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)